F 0656
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Some
Develop and implement a complete care plan that meets all the resident's needs, with timetables and
actions that can be measured.
Based on observation, interview and record review, the facility did not create a care plan for one of two
residents (Resident 11) who was on supplemental oxygen (O2) for 7 months. This failure could result to
oxygen toxicity or oxygen poisoning (lung damage that happens from breathing in too much extra
[supplemental] oxygen), which can cause coughing, trouble breathing, and in severe cases it could
potentially cause death.
Findings:
During the initial tour of the facility on 07/25/23 at 11:36 AM, Resident 11 was observed seated in her
wheelchair at the bedside. Resident 11 was on O2 via a nasal cannula (a thin tube which delivers oxygen
into the nose) and was receiving the O2 at two Liters (unit of volume) Per Minute (2 LPM).
During a follow-up visit on 07/27/23 at 11:19 AM, Resident 11 was on O2 via nasal cannula at 2 LPM.
During a review of records on 07/27/23 at 11:54 AM, Resident 11's face sheet (one-page summary of
important information about a patient including patient identification, past medical history, medications,
allergies, insurance status, or other pertinent information) indicated Resident 11 was admitted at the facility
on 11/2/22 with a diagnosis of generalized blood infection (sepsis) urinary tract infection, history of
COVID-19 infection and major depression among other conditions. A change in condition report dated
11/24/22 indicated Resident 11 appeared withdrawn, flushed but afebrile (no fever) with oxygen saturation
(SpO2 - the amount of oxygen circulating in the blood) of 87% on room air (87% RA). A physician's order
dated 12/20/22, indicated, oxygen at 1-2 LPM via nasal cannula as needed (PRN) to keep oxygen
saturation above 92% for hypoxia (low levels of oxygen in the blood).
During an interview on 07/27/23, at 11:46 AM, Nurse Resource stated Resident 11 was placed on O2 in
November 2022 after her O2 saturation was low. When asked where the care plan for the oxygen
administration was, Nurse Resource stated they were looking for the care plan.
During an interview on 07/27/23 at 12:31 PM, the Director of Staff Development (DSD) provided the order
detail for Resident 11's oxygen and stated the order was for an as needed oxygen administration. When
asked if there was a care plan with the order, especially since Resident 11 was on oxygen since 12/2022,
the DSD did not have a response.
A review of the facility policy titled Policy/procedure - Nursing Administration on care planning revised
2/2023 indicated it is the policy of the facility that the interdisciplinary team (IDT) shall develop a
comprehensive care plan for each resident. Revision or updating of the care plan will occur upon significant
changes of condition, etc. The policy failed to discuss the purpose of care
(continued on next page)
Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other
safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the
date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date
these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.
LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER
REPRESENTATIVE'S SIGNATURE
TITLE
(X6) DATE
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Facility ID:
If continuation sheet
Page 1 of 11
Event ID:
555258
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
555258
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
07/28/2023
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Valley of the Moon Post Acute
347 Andrieux St
Sonoma, CA 95476
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0656
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Some
FORM CMS-2567 (02/99)
Previous Versions Obsolete
plans in describing the resident's medical, nursing, physical, mental and psychosocial needs and
preferences and how the facility will assist in meeting these needs and preferences. The policy also did not
indicate care plans must include person-specific, measurable objectives and timeframes in order to
evaluate the resident ' s progress toward his/her goal(s). The policy did not indicate that if care planning is
not complete, or is inadequate, the consequences may negatively impact the resident ' s quality of life, as
well as the quality of care and services received. Lastly, the policy did not indicate when and how a
resident's care plan was reviewed and evaluated if effective or needed updates.
Event ID:
Facility ID:
555258
If continuation sheet
Page 2 of 11
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
555258
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
07/28/2023
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Valley of the Moon Post Acute
347 Andrieux St
Sonoma, CA 95476
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0727
Level of Harm - Minimal harm
or potential for actual harm
Have a registered nurse on duty 8 hours a day; and select a registered nurse to be the director of nurses on
a full time basis.
Based on interviews, and record review, the facility failed to provide the services of a Director of Nursing
(DON) on a full time basis for the last thee months.
Residents Affected - Many
This failure prevented the oversight of a professional Registered Nurse (RN) in the management and
direction of all aspects of the nursing services department that could adversely impact the care and
treatment of residents residing in the facility.
Findings:
During an interview on 7/24/23, at 11:52 AM, the Administrator stated the facility did not have a Director of
Nursing.
During an interview on 7/27/23, at 3:15, the Director of Staff Development (DSD) stated the facility did not
have a full time DON since early 4/2023.
During a follow-up interview on 7/28/23, at 2:29 PM, the Administrator stated he had been the Administrator
since 1/2023 and the facility had been without a DON since 4/2023. The Administrator stated the facility
already had a corrective action plan and prospects for the position of DON but wanted to ensure they hired
a candidate who will best fit the position.
A review of the facility document titled, Facility assessment tool dated 3/27/23, indicated, the facility will
ensure they have sufficient staff to meet the needs of the identified resident population at any given time by
ensuring the services of an RN as full time DON and other nursing professional.
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
555258
If continuation sheet
Page 3 of 11
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
555258
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
07/28/2023
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Valley of the Moon Post Acute
347 Andrieux St
Sonoma, CA 95476
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0755
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Some
Provide pharmaceutical services to meet the needs of each resident and employ or obtain the services of a
licensed pharmacist.
Based on observations and a review of records, it was determined that the facility failed to meet the
pharmaceutical needs of its residents by not having proper procedures in place to ensure the accurate
administration of all drugs. Specifically, during the administration of an insulin injection to Resident 25, it
was observed that the injection site was not rotated, and the same site was used multiple times by several
different nurses. This could potentially lead to an adverse reaction such as lipodystrophy (a disorder that
affects how the body accumulates and stores fat).
Findings:
A review of the Lispro insulin manufacture's insert indicated that Lispro was a type of medicine that helps
people with diabetes keep their blood sugar at a healthy level. Lispro subcutaneous administration (given as
a shot under the skin) should be given in different places on the body like the stomach, thigh, upper arm, or
buttocks. It's important to rotate (change where the shot is given each time) the injection site so that the
skin stays healthy. This is because long-term use of Lispro insulin can cause lipodystrophy at the site of
repeated insulin injections. Lipodystrophy is a disorder that affects how the body accumulates and stores
fat.
During an observation on 7/24/23, at 4:30 PM, LVN A administered Lispro to Resident 25. Prior to the
administration, LVN A did not check the previous injection site. It was observed that LVN A administered
Lispro to Resident 25's left arm without knowledge of the previous injection location. A review of Resident
25's electronic record on 07/24/23 showed that Lispro was administered in the left arm at 7:59 AM. During
an observation on 7/24/23 at 4:30 PM, LVN A was seen administering the next dose of Lispro, again
injecting it into the left arm.
A review on 7/24/23 of Resident 25's Medication Administration Record (MAR), conducted after
observation and an interview with the LVN A, revealed a failure to rotate the insulin administration sites by
multiple different nurses during the months of June and July. The following injection sites were not rotated
as follows:
6/7/2023:
- Bedtime dose administered insulin in the lower upper quadrant of the abdomen.
- Next dose administered insulin in the lower upper quadrant of the abdomen.
6/9/2023:
- Afternoon dose administered insulin in the left arm.
- Administered next dose insulin in the left arm.
6/11/2023:
- Evening dose Administered insulin in the left arm.
- Administered next dose insulin in the left arm.
(continued on next page)
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
555258
If continuation sheet
Page 4 of 11
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
555258
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
07/28/2023
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Valley of the Moon Post Acute
347 Andrieux St
Sonoma, CA 95476
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0755
- Administered next dose insulin in the left arm.
Level of Harm - Minimal harm
or potential for actual harm
- Administered next dose insulin in the left arm.
6/13/2023:
Residents Affected - Some
- Administered morning dose insulin in the left arm.
- Administered next dose insulin in the left arm.
- Administered next dose insulin in the left arm.
6/15/2023:
- Administered bedtime insulin in the right arm.
- Administered next dose insulin in the right arm.
6/16/2023:
- Administered bedtime insulin in the left arm.
- Administered next dose insulin in the left arm.
- Administered next dose insulin in the left arm.
6/18/2023:
- Administered evening dose of insulin in the left arm.
- Administered next dose insulin in the left arm.
- Administered next dose insulin in the left arm.
6/20/2023:
- Administered evening dose of insulin in the left arm.
- Administered next dose insulin in the left arm.
- Administered next dose insulin in the left arm.
6/21/2023:
- Administered afternoon dose of insulin in the Right Lower Quadrant.
- Administered next dose in the Right Lower Quadrant.
07/01/23:
(continued on next page)
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
555258
If continuation sheet
Page 5 of 11
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
555258
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
07/28/2023
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Valley of the Moon Post Acute
347 Andrieux St
Sonoma, CA 95476
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0755
-Evening dose administration to the right lower quadrant of the abdomen.
Level of Harm - Minimal harm
or potential for actual harm
-Next dose administration to the right lower quadrant of the abdomen.
07/07/23:
Residents Affected - Some
-Morning dose administration to the right lower quadrant of the abdomen.
-Next dose administration to the right lower quadrant of the abdomen.
07/16/23:
-Afternoon dose administration was performed on the left arm.
-Next dose administration was performed on the left arm.
07/24/23:
-Morning dose administration was performed on the left arm.
-Next dose administration was performed on the left arm.
-Next dose administration was performed on the left arm.
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
555258
If continuation sheet
Page 6 of 11
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
555258
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
07/28/2023
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Valley of the Moon Post Acute
347 Andrieux St
Sonoma, CA 95476
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0756
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Some
Ensure a licensed pharmacist perform a monthly drug regimen review, including the medical chart,
following irregularity reporting guidelines in developed policies and procedures.
Based on interviews and record reviews, it was discovered that the facility pharmacist failed to report
irregularities, and the facility itself did not take appropriate action in response to these irregularities. The
facility pharmacist failed to identify the lack of insulin site rotation for Resident 25, which resulted in the
resident at risk for lipodystrophy due to repeated injection at the same site. Lipodystrophy is a disorder that
affects how the body accumulates and stores fat.
Findings:
During a review on 7/24/23 of Resident 25's Medication Administration Record (MAR) and following an
observation and interview with LVN A, a concerning pattern was identified. Multiple different nurses had
failed to rotate the insulin administration sites properly, which raised concerns about the potential
development of complications. The number of instances of non-rotated injection sites were as follows:
6/7/2023:
- Bedtime dose administered insulin in the lower upper quadrant of the abdomen.
- Next dose administered insulin in the lower upper quadrant of the abdomen.
6/9/2023:
- Afternoon dose administered insulin in the left arm.
- Administered next dose insulin in the left arm.
6/11/2023:
- Evening dose Administered insulin in the left arm.
- Administered next dose insulin in the left arm.
- Administered next dose insulin in the left arm.
- Administered next dose insulin in the left arm.
6/13/2023:
- Administered morning dose insulin in the left arm.
- Administered next dose insulin in the left arm.
- Administered next dose insulin in the left arm.
6/15/2023:
(continued on next page)
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
555258
If continuation sheet
Page 7 of 11
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
555258
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
07/28/2023
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Valley of the Moon Post Acute
347 Andrieux St
Sonoma, CA 95476
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0756
- Administered bedtime insulin in the right arm.
Level of Harm - Minimal harm
or potential for actual harm
- Administered next dose insulin in the right arm.
6/16/2023:
Residents Affected - Some
- Administered bedtime insulin in the left arm.
- Administered next dose insulin in the left arm.
- Administered next dose insulin in the left arm.
6/18/2023:
- Administered evening dose of insulin in the left arm.
- Administered next dose insulin in the left arm.
- Administered next dose insulin in the left arm.
6/20/2023:
- Administered evening dose of insulin in the left arm.
- Administered next dose insulin in the left arm.
- Administered next dose insulin in the left arm.
6/21/2023:
- Administered afternoon dose of insulin in the Right Lower Quadrant.
- Administered next dose in the Right Lower Quadrant.
The consistent lack of rotation of injection sites raises concerns about the potential risk of lipodystrophy
and other complications for Resident 25. It is essential that the facility addresses this issue and reinforces
proper insulin administration protocols to safeguard the well-being of all residents under their care.
During an interview conducted on 07/24/23 at 3:40 PM with RPH C, RPH C stated that the failure of nurses
to rotate injection sites was an irregularity that should be addressed promptly to prevent the development of
lipodystrophy. RPH C stated that he should have identified and reported this issue of improper
implementation of injection site rotation for Lispro, but he had difficulties with his computer. He
acknowledged that nurses should be rotating the injection site.
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
555258
If continuation sheet
Page 8 of 11
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
555258
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
07/28/2023
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Valley of the Moon Post Acute
347 Andrieux St
Sonoma, CA 95476
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0759
Ensure medication error rates are not 5 percent or greater.
Level of Harm - Minimal harm
or potential for actual harm
Based on observations, interviews, and a review of records, it was found that the facility failed to maintain a
medication error rate of less than 5%. During the medication pass, three medication errors were observed
out of twenty-nine opportunities, resulting in an error rate of 10%.
Residents Affected - Some
Findings:
1. A review of the Lispro insulin manufacturer's insert indicated that Lispro is a type of medicine that helps
people with diabetes keep their blood sugar at a healthy level. Lispro subcutaneous administration (given as
a shot under the skin) should be given in different places on the body like the stomach, thigh, upper arm, or
buttocks. It's important to rotate (change where the shot is given each time) the injection site so that the
skin stays healthy. This is because long-term use of Lispro insulin can cause lipodystrophy at the site of
repeated insulin injections. Lipodystrophy is a disorder that affects how the body accumulates and stores
fat.
A review of Resident 25's electronic record on 7/24/23, it was noted that the physician had ordered a sliding
scale (a way to adjust the amount of insulin you take) of Lispro to be administered based on the resident's
blood sugar levels. The doctor's orders specified that Lispro should be administered accordingly.
During an observation on 7/24/23, at 4:30 PM, LVN A administered Lispro to Resident 25. Prior to the
administration, LVN A did not check the previous injection site. It was observed that LVN A administered
Lispro to Resident 25's left arm without knowledge of the previous injection location.
A review of Resident 25's electronic record on 07/24/23 showed that Lispro was administered in the left arm
at 7:59 AM. During an observation on 7/24/23 at 4:30 PM, LVN A was seen administering the next dose of
Lispro, again injecting it into the left arm.
During the interview on 7/24/23, at 4:45 PM, LVN A admitted to not reviewing the previous injection site
administration in Resident 25's electronic record. LVN A also acknowledged forgetting to check prior to
administration. She expressed her commitment to improving her performance in the future.
2. A review on 7/25/23 of the MiraLAX Manufacturer's insert indicated that MiraLAX is an over-the-counter
medication used to treat occasional constipation. It works by increasing the amount of water in the intestinal
tract to stimulate bowel movements. According to the MiraLAX package insert, after mixing the powder with
a liquid, you should stir the mixture well until it completely dissolves and drink it right away. Do not save it
for later use.
A review of Resident 5's electronic record on 7/24/23, it was noted that the physician had ordered MiraLAX.
The doctor's orders specified that MiraLAX should be administered accordingly.
During an observation on 7/25/23 at 8:15 AM it was observed that LVN B had prepared MiraLAX with
approximately of 5 oz of water. The MiraLAX mixture was handed to Resident 5 and then Resident 5
decided to place it on the bed side table. During the observation Resident 5 did not drink her MiraLax.
During an observation of 7/25/23 at 9:15 AM Resident 5 was sitting in bed alone with a full glass of
MiraLAX. The MiraLAX remained on the table for an hour. When asked about it, Resident 5 stated that she
was unaware that it was medication.
(continued on next page)
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
555258
If continuation sheet
Page 9 of 11
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
555258
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
07/28/2023
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Valley of the Moon Post Acute
347 Andrieux St
Sonoma, CA 95476
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0759
Level of Harm - Minimal harm
or potential for actual harm
During an interview on 7/25/23, at 10:45 AM LVN B, stated that he had administered MiraLAX for Resident
5. He mentioned giving the medication to Resident 5 and witnessed Resident 5 picking up the cup of
MiraLAX and placing it on the bedside tray table. However, LVN B admitted to leaving the room without
verifying if Resident 5 had taken the medication. The LVN B acknowledged this oversight and expressed
their intention to improve in the future.
Residents Affected - Some
3. Advair Diskus is a combination medication that contains two active ingredients: fluticasone propionate,
which is a corticosteroid, and salmeterol, which is a long-acting bronchodilator. The medication is used to
prevent asthma attacks and to prevent flare-ups or worsening of chronic obstructive pulmonary disease
(COPD) associated with chronic bronchitis and/or emphysema.
The manufacturer of Advair Diskus provides the following instructions for using the Advair Diskus:
*Open the Diskus device by holding the outer case in one hand and putting the thumb of your other hand
on the thumb grip. Push the thumb grip away from you as far as it will go until the mouthpiece and lever are
revealed.
*Slide the lever away from you until it clicks into place. This loads a dose of medication.
*Breathe out fully to empty your lungs, but do not breathe into the Diskus device.
*Place the mouthpiece of the Diskus device in your mouth and close your lips around it, making sure not to
block it with your teeth or tongue.
*Breathe in quickly and deeply through your mouth to draw the medication into your lungs.
*Hold your breath for about 10 seconds or as long as comfortable to allow the medication to be fully
absorbed.
*Breathe out slowly and smoothly, away from the Diskus device.
*Close the Diskus device by sliding the thumb grip back towards you as far as it will go until it clicks into
place, covering the mouthpiece.
*After using the Diskus device, rinse your mouth with water without swallowing to help reduce the risk of
oropharyngeal candidiasis.
A review of Resident 24's electronic record on 7/24/23, it was noted that the physician had ordered Advair
Diskus. The doctor's orders specified that Advair Diskus should be administered accordingly.
During an observation 7/25/23 at 8:45 AM LVN A prepared and administered Advair to Resident 24.
However, Resident 24 did not hold her breath after inhaling the medication and was not instructed to do so.
Holding one's breath for about 10 seconds after inhaling the medication from Advair Diskus allows the
medication to settle into the airways and lungs, where it can be fully absorbed and start working to improve
breathing. This is an important step in ensuring that the full benefit of the medication is received.
During an interview on July 25, 2023, at 11:05 AM, LVN A stated that she had not instructed Resident 24 to
hold her breath after administering Advair. LVN A acknowledged that she was unaware of the
(continued on next page)
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
555258
If continuation sheet
Page 10 of 11
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
555258
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
07/28/2023
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Valley of the Moon Post Acute
347 Andrieux St
Sonoma, CA 95476
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0759
manufacturer's recommendation to hold one's breath after inhaling the medication and expressed a
commitment to improving her practice in the future.
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Some
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
555258
If continuation sheet
Page 11 of 11